ScholarIQanswers from OpenAlex

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

PaperCitations, authors & open-access status

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy have?

ScholarIQcitation count

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy has 329 citations in the OpenAlex counts ScholarIQ stores.

When was Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy published?

ScholarIQyear

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy has 2021 year in the ScholarIQ index.

What is the open-access status of Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy?

ScholarIQoa status

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy has gold oa status in the ScholarIQ index.

What is the DOI of Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy?

ScholarIQdoi

The DOI for Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy is on the source record.

What is the PMID of Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy?

ScholarIQpmid

The PMID for Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy is on the source record.

What is the OpenAlex record for Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy?

ScholarIQopenalex

The OpenAlex for Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial